Home Blog Tag Mc1r agonist

MC1R agonist

Mar 31, 2026

Tanabe Pharma Shares Encouraging Phase 3 Data for Dersimelagon in Rare Photodermatoses; Biogen’s Litifilimab Demonstrates Significant Skin Disease Reduction in Phase 2 CLE Trial; Merck’s WINREVAIR Shows Promising Phase 2 Results in CpcPH-HFpEF Population; AstraZeneca’s Tozorakimab Meets Primary Endpoints in OBERON and TITANIA Phase III COPD Trials; Amgen’s REPATHA Shows Strong Cardiovascular Risk Reduction in High-Risk Patients

Tanabe Pharma Reports Positive Phase 3 INSPIRE Results for Dersimelagon in EPP and XLP Tanabe Pharma Corporation has announced detailed findings from the Phase 3 INSPIRE trial evaluating investigational oral dersimelagon in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The ...